Anthony Daddono
Gurnee, ILNPI 1013919976
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 248 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,404 and has fallen 50.4% since, to $696 in 2023.
Across 248 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$980
- GSK$868
- Boehringer Ingelheim$452
- Covis Pharma GmbH$447
- Mylan Specialty L.p.$429
- Sanofi$346
- plus $2K from 18 others
What the payments were for
- Food & beverage$5,059100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 41 | $980 |
| GSK | 56 | $868 |
| Boehringer Ingelheim | 21 | $452 |
| Covis Pharma GmbH | 25 | $447 |
| Mylan Specialty L.p. | 17 | $429 |
| Sanofi | 11 | $346 |
| Teva Pharmaceuticals USA, Inc. | 13 | $299 |
| Genentech USA, Inc. | 15 | $289 |
| Regeneron Healthcare Solutions, Inc. | 10 | $266 |
| Optinose US, Inc. | 12 | $198 |
| Kaleo, Inc. | 4 | $94 |
| Amgen | 4 | $65 |
| Sanofi-aventis U.S. LLC | 3 | $56 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $40 |
| Merck | 2 | $33 |
| Novartis | 2 | $33 |
| Alk-abello, Inc | 2 | $32 |
| Hikma Pharmaceuticals USA | 2 | $31 |
| Blueprint Medicines Corporation | 1 | $30 |
| Tersera Therapeutics LLC | 1 | $20 |
| Aimmune Therapeutics, Inc. | 1 | $19 |
| AbbVie | 1 | $16 |
| USWM, LLC | 1 | $15 |
| Eyevance Pharmaceuticals LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Montelukast Sodium | 18 | $260 |
Paid to pharmacies, not to this prescriber.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.